Combined SGLT2 and DPP4 Inhibition Reduces the Activation of the Nlrp3/ASC Inflammasome and Attenuates the Development of Diabetic Nephropathy in Mice with Type 2 Diabetes

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes

Bruce Neal, Vlado Perkovic, Kenneth W. Mahaffey et al. · New England Journal of Medicine · 2017 · 7.5K citations · Full text

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes

Steven P. Marso, Gilbert H. Daniels, Kirstine Brown‐Frandsen et al. · New England Journal of Medicine · 2016 · 7K citations · Full text

Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes

Christoph Wanner, Silvio E. Inzucchi, John M. Lachin et al. · New England Journal of Medicine · 2016 · 3.5K citations · Full text

Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1β in type 2 diabetes

Seth L. Masters, Aisling Dunne, Shoba Subramanian et al. · Nature Immunology · 2010 · 1.3K citations · Full text

Inflammation, Autoimmune Disease, Diabetes +13

Liraglutide and Renal Outcomes in Type 2 Diabetes

Johannes F.E. Mann, David D. Ørsted, Kirstine Brown‐Frandsen et al. · New England Journal of Medicine · 2017 · 1.2K citations · Full text